Related Experiment Video
Updated: May 16, 2026
E-Patient Counseling Trial (E-PACO): Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
Published on: August 1, 2019
Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory
Lieven Mulders1, Maarten Pruijt1, Joep Van Oostrom1
1Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands.
Background:
Hyperbaric oxygen therapy (HBOT) delivers 100% oxygen in a pressurized chamber and enhances tissue oxygenation and neovascularization. While effective in radiation proctitis, acute severe ulcerative colitis, and perianal fistulizing Crohn's disease, its role in refractory ulcerative colitis (UC) remains underexplored.
Methods:
PARADOX was a prospective, open-label, phase 2a pilot trial in biologic-experienced patients with moderate-to-severe refractory UC (total Mayo > 5, Mayo endoscopic subscore (MES) ≥ 2, failure of ≥ 2 advanced therapies). Patients received 10 or 20 daily HBOT sessions (2.4 atmospheres absolute, 120 minutes/day) while continuing stable background therapy. The primary endpoint was composite clinical and endoscopic response at week 12 (≥ 3-point and 30% Mayo score reduction, rectal bleeding score = 0, and ≥ 1-point decrease in MES). Secondary outcomes included symptomatic, biochemical, and transmural response by intestinal ultrasound (IUS), including perfusion metrics via contrast-enhanced ultrasound (CEUS).
Results:
In total, 16 patients (8 per group) were included in this pilot study. At week 12, composite response was achieved in 2/8 (10-session) and 4/8 (20-session) patients. Improvements in clinical, endoscopic, and IUS parameters were observed in both groups. Clinical responders showed increased CEUS perfusion at week 12 (peak enhancement Δ12.1 dB), while non-responders declined (Δ -5.4 dB). This pattern was consistent across wash-in/wash-out metrics, supporting a volume perfusion-based response. HBOT was well tolerated, with no serious adverse events or treatment discontinuations.
Conclusion:
HBOT is a well-tolerated adjunctive therapy in refractory UC, which improved clinical outcomes and perfusion kinetics. These findings support further evaluation in a randomized, dose-optimized trial.Euclinicaltrials.eu, EU CT number 2024-515278-28-00.
Related Concept Videos
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Drugs for Treatment of Ulcerative Colitis in IBD
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...